Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1421-1430 Newer>

The Motley Fool September 28, 2004 Brian Gorman	Fat Profits? Nastech makes a deal with Merck to develop an obesity drug.
The Motley Fool September 28, 2004 Brian Gorman	Cambrex's Dose of Reality The biopharma's outlook is cloudy due to stiffer competition in biomanufacturing.
BusinessWeek October 4, 2004 Kerry Capell	Why Glaxo Can't Shake the Flu Sales are weakening as hot sellers come off-patent. But the pipeline looks healthy. And there's the rub. Just when GSK's image is at a new low, its prospects are improving.
BusinessWeek October 4, 2004	"It's a Perfect Storm" for Drugmakers Glaxo CEO Jean-Pierre Garnier answers questions about the biotech industry's hardships and how his company is improving its search for new drugs
The Motley Fool September 24, 2004 Brian Gorman	Emisphere Wins Novartis Over The drug delivery company warrants close attention, although massive profits are not in the near-term cards.
The Motley Fool September 24, 2004 Charly Travers	BioMarin Blew It Big-Time On Tuesday the company revised its financial guidance for the year with anticipated revenues from recently acquired drug Orapred coming in at a whopping total of zero.
Bio-IT World September 16, 2004 Michael A. Greeley	Platforms for Pathways Investor interest in the next great blockbuster drug has been blistering hot; Phase II and Phase III compound companies are being funded at a near record-breaking pace now that the IPO window seems to be slightly open
BusinessWeek October 4, 2004 Gene G. Marcial	A New Owner For Aspect? Some pros say Aspect Medical Systems may be in play. Shares have leaped to $17, up from $13.
BusinessWeek October 4, 2004 Gene G. Marcial	TriPath Imaging: The Prognosis Is Good Another diagnostic outfit has caught the eye of investors. Its stock, at $10 in April, sild to $7 in August but has since crept up to $8.30.
The Motley Fool September 23, 2004 Rich Duprey	Dentsply Is More Than a Mouthful Dental supply company increases cash dividend by 14% amid torrid growth.
<Older 1421-1430 Newer> Return to current articles.